skip to Main Content

GYN References

This page lists publications that have been referenced by our Specialists during a session.

1) American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part I: general principles.
Viswanathan AN. Thomadsen B. American Brachytherapy Society Cervical Cancer Recommendations Committee. American Brachytherapy Society. Brachytherapy. 2012; 11(1):33-46.

2) American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part III: low-dose-rate and pulsed-dose-rate brachytherapy. Lee LJ. Das IJ. Higgins SA. Jhingran A. Small W Jr. Thomadsen B. Viswanathan AN. Wolfson A. Eifel P. American Brachytherapy Society. Brachytherapy. 2012; 11(1):53-7.

3) An Atlas of the Pelvic Lymph Node Regions to Aid Radiotherapy Target Volume Definition. Taylor, A, Rockall, AG, Powell, MEB. Clinical Oncology. 2007; 19: 542-550.

4) Combined chemotherapy and radiation improves survival for node-positive endometrial cancer. Larissa J. Lee, Akila N. Viswanathan. Gynecologic Oncology. 2012;127(1):32-37.

5) Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix. Peters, WA, Liu, PY, Rolland, J, et al. Journal of Clinical Oncology. 2000; 18(8): 1606-1613.

6) Consensus Guidelines for Delineation of Clinical Target Volume For Intensity-Modulated Pelvic Radiotherapy in  Postoperative Treatment of Endometrial and Cervical Cancer. Small, W, Mell, LK, Anderson, P, et al. International Journal of  Radiation Oncology Biology Physics. 2008; 71(2): 428-434.

7) Consensus recommendations for intensity modulated radiation therapy planning for post-operative pelvic radiotherapy in
endometrial cancer. Small W, Mell LK, Creutzberg C, et al. International Journal of Radiation Oncology Biology Physics. 2008;71:428-34.

8) Contouring inguinal and femoral nodes; how much margin is needed around the vessels? Carolyn H. Kim, Adam C. Olson, Hayeon Kim, Sushil Beriwal. Practical Radiation Oncology. 2012 2(4):274-278.

9) Dose and Volume Parameters for MRI-based Treatment Planning in Intracavitary Brachytherapy for Cervical Cancer. Kirisits, C, Pötter, R, Lang, S, Dimopoulos, J, Wachter-Gerstner, N, Georg, D. International Journal of Radiation Oncology Biology Physics. 2005; 62(3):901-11.

10) Dose Effect Relationship for Late Side Effects of the Rectum and Urinary Bladder in Magnetic Resonance Image-guided Adaptive Cervix Cancer Brachytherapy. Georg, P, Pötter, R, Georg, D, Lang, S, Dimopoulos, JC, Sturdza, AE, Berger, D, Kirisits, C, Dörr, W. International Journal of Radiation Oncology Biology Physics. 2012;82(2):653-7.

11 ) Dose-volume Histogram Parameters and Late Side Effects in Magnetic Resonance Image-guided Adaptive Cervical Cancer Brachytherapy. Georg, P, Lang, S, Dimopoulos, JC, Dorr, W, Sturdza, AE, Berger, D, Georg, D, Kirisits, C, Potter, R. International Journal of Radiation Oncology Biology Physics. 2011;79(2):356-62.

12) Duodenal and Other Gastrointestinal Toxicity in Cervical and Endometrial Cancer Treated With Extended-Field Intensity Modulated Radiation Therapy to Paraaortic Lymph Nodes. Philip D. Poorvu, Cheryl A. Sadow, Kanokpis Townamchai, Antonio L. Damato, Akila N. Viswanathan. International Journal of Radiation Oncology Biology Physics. 2013; 85(5):1262-1268.

13) Early stage papillary serous or clear cell carcinoma confined to or involving an endometrial polyp: outcomes with and without adjuvant therapy. Christine N. Chang-Halpenny, Sathima Natarajan, Julie Hwang-Graziano. Gynecologic Oncology. 2013;131(3): 598-603

14) Final analysis of RTOG 9708: Adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. Kathryn Greven, Kathryn Winter, Kelly Underhill, Jim Fontenesci, Jay Cooper, Tom Burke. Gynecologic Oncology. 2006; 103(1):155-159.

15)  Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer. Kiess AP, Damast S, Makker V, Kollmeier MA, Gardner GJ, Aghajanian C, Abu-Rustum NR, Barakat RR, Alektiar KM. Gynecolgic Oncology. 2012; 127(2):321-5.

16) Impact of 3D image-based PDR brachytherapy on outcome of patients treated for cervix carcinoma in France: Results of the French STIC prospective study.  Claire Charra-Brunaud, Valentin Harter, Martine Delannes, et al. Radiotherapy and Oncology. 2012; 103: 305–313.

17) Impact of dosimetric and clinical parameters on clinical side effects in cervix cancer patients treated with 3D pulse-dose-rate intracavitary brachytherapy. Mihai Levitchi, Claire Charra-Brunaud, Philippe Quetin, et al. Radiotherapy and Oncology; 2012;103: 314–321.

18) Integrated genomic characterization of endometrial carcinoma. The Cancer Genome Atlas Research Network. Nature. 2013; 497: 67–73.

19) Intravaginal High-Dose-Rate Brachytherapy for Stage I Endometrial Cancer: a Randomized Study of Two Dose-Per-Fraction Levels. Sorbe, B, Straumits, A, Karlsson, L. International Journal of Radiation Oncology Biology Physics.

20) Intensity-modulated radiotherapy for the treatment of vulvar carcinoma: A comparative dosimetric study with early clinical outcome. Sushil Beriwal, Dwight E. Heron, Hayeon Kim, Gwendolyn King, et al. International Journal of Radiation Oncology Biology Physics. 2006; 84(5): 1395-1400.

21) Low-Stage Ovarian Clear Cell Carcinoma: Population-Based Outcomes in British Columbia, Canada, With Evidence for a Survival Benefit As a Result of Irradiation. Paul J. Hoskins, Nhu Le, Blake Gilks, Anna Tinker, Jennifer Santos, Frances Wong and Kenneth D. Swenerton. Journal of Clinical Oncology. 2012;30(14): 1656-1662.

22) Mapping Pelvic Lymph Nodes: Guidelines for Delineation in Intensity-Modulated Radiotherapy. Taylor, A, Rockall, AG, Reznek, RH, et al. International Journal of Radiation Oncology Biology Physics. 2005; 63(5): 1604- 1612.

23) Multivariate Analysis of Para-aortic Lymph Node Recurrence After Definitive Radiotherapy for Stage IB-IVA Squamous Cell Carcinoma of Uterine Cervix.  Huang EY, Wang CJ, Chen HC, Fang FM, Huang YJ, Wang CY, Hsu HC. International Journal of Radiation Oncology Biology Physics. 2008;72(3):834-42.

24) Outcomes after radiation therapy with concurrent weekly platinum-based chemotherapy or every-3-4-week 5-fluorouracil-containing regimens for squamous cell carcinoma of the vulva. Mak RH, Halasz LM, Tanaka CK, Ancukiewicz M, Schultz DJ, Russell AH, Viswanathan AN. Gynecologic Oncology. 2011;120(1):101-7.

25) Preoperative Intensity Modulated Radiation Therapy and Chemotherapy for Locally Advanced Vulvar Carcinoma: Analysis of Pattern of Relapse. Sushil Beriwal, Gaurav Shukla, Ashwin Shinde, Dwight E. Heron, et al. International Journal of Radiation Oncology Biology Physics. 2013; 85(5):1269-1274.

26) A Phase III Randomized Trial of Postoperative Pelvic Radiation in Stage IB Cervical Carcinoma with Poor Prognostic Features: Follow-up of a Gynecologic Oncology Group Study.  Rotman, M, Sedlis, A, Piedmonte, MR, et al. International Journal of Radiation Oncology Biology Physics. 2006; 65: 169-176.

27) Radiation dose escalation using intensity modulated radiation therapy for gross unresected node-positive endometrial cancer
Kanokpis Townamchai, MD, Philip D. Poorvu, MD, Antonio L. Damato, PhD, Rebecca DeMaria, BA, Larissa J. Lee, MD, Suzanne Berlin, DO, Colleen Feltmate, MD, Akila N. Viswanathan, MD. Practical Radiation Oncology. Published online 04 September 2013.

28) Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, Favini G, Ferri L, Mangioni C. Lancet. 1997 Aug 23;350(9077):535-40.

29) A Randomized Trial of Pelvic Radiation Therapy versus No Further Therapy in Selected Patients with Stage IB Carcinoma of the Cervix after Radical Hysterectomy and Plevic Lymphadenectomy: A Gynecologic Oncology Group Study. Sedlis, A, Bundy, BN, Rotman, MZ, et al. Gynecologic Oncology. 1998; 73: 177-183.

30) The role of vaginal brachytherapy in the treatment of surgical stage I papillary serous or clear cell endometrial cancer.
Barney BM, Petersen IA, Mariani A, Dowdy SC, Bakkum-Gamez JN, Haddock MG.  International Journal of Radiation Oncology Biology Physics. 2013; 85(1):109-15.

31)  A systematic review and meta-analysis of probiotics for the management of radiation induced bowel disease.
Hamad A, Fragkos KC, Forbes A. Clinical Nutrition. 2013 Jun;32(3):353-60.

32) Vaginal brachytherapy for early stage uterine papillary serous and clear cell endometrial cancer. Kanokpis Townamchai, Ross Berkowitz, Mandar Bhagwat, Antonio L. Damato, Scott Friesen, Larissa J. Lee, Ursula Matulonis, Desmond O’Farrell, Akila N. Viswanathan. Gynecologic Oncology. 2013;129(1)18-21.

33) Vaginal Motion and Bladder and Rectal Volumes During Pelvic Intensity-Modulated Radiation Therapy After Hysterectomy  Jhingran, A, Salehpour, M, Sam, M, et al. International Journal of Radiation Oncology Biology Physics. 2012: 82(1): 256-262.

34) A Verification study of Proposed Pelvic Lymph Node Localisation Guidelines Using Nanoparticle-enhanced Magnetic Resonance Imaging. Vilarino-Valera, MJ, Taylor, A, Rockall, AG, et al. Radiotherapy and Oncology.  2008; 89: 192-196.

Back To Top